Trial Profile
An Open-Label Phase 2a Study Evaluating the Safety and Efficacy of Combination Treatment With 2 Weeks of the Non-Nucleoside Inhibitor CDI 31244 Plus 6 Weeks of Sofosbuvir/Velpatasvir in Subjects With Chronic Hepatitis C Genotype 1 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2021
Price :
$35
*
At a glance
- Drugs CC 31244 (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Cocrystal Pharma Inc
- 16 Nov 2020 According to a Cocrystal Pharma Inc. media release, the company with its collaborators from the University of Maryland has published results from this 2a study in the Journal of Medical Virology, November 5, 2020.
- 14 May 2020 Results published in the Cocrystal Pharma Inc media release
- 30 Mar 2020 According to a Cocrystal Pharma Inc media release, the full study report of this trial is expected in the first quarter 2020.